Skip to main content
Premium Trial:

Request an Annual Quote

De-Extinction Firm Colossal Biosciences Raises $150M in Series B Round


NEW YORK — Colossal Biosciences, which aims to use gene editing and other technologies to restore extinct animal species, said on Tuesday that it has raised $150 million in Series B funding.

The financing round was led by United States Innovative Technology Fund and included Breyer Capital, WestRiver Group, Bob Nelsen, Animal Capital, Victor Vescovo, In-Q-Tel, Animoca Brands, Peak 6, Bold Capital, and Jazz Ventures. Colossal, which launched in late 2021 with $15 million in seed funding and closed a $60 million Series A round about a year ago, has raised $225 million to date.

In conjunction with the Series B announcement, Colossal said that it has formed an avian genomics division that will be focused on restoring and reintroducing the extinct dodo bird. The Dallas-based company is currently working to restore the woolly mammoth and the Tasmanian tiger.

Colossal also recently spun out a new company, called Form Bio, to commercialize its bioinformatics and computational biology technology platform.

The Scan

Cystatin C Plays Role in Immunosuppression, Cancer Immunotherapy Failure, Study Finds

A study in Cell Genomics provides insight into how glucocorticoids can lead to cancer immunotherapy failure via cystatin C production.

Aging, Species Lifespan Gene Expression Signatures Overlap

An Osaka Metropolitan University team reports in Nucleic Acids Research that transcriptional signatures of aging and maximum lifespan have similarities.

Splicing Subgroup Provides Protocols for Evaluating Splicing Variant Data

The group presents their approach on how to apply evidence codes to splicing predictions and other data in the American Journal of Human Genetics.

Single-Cell Transcriptomic Atlas of Mouse Cochlea to Aid Treatment Development

Researchers in PNAS conducted single-cell and single-nuclear sequencing of about 120,000 cells at three key timepoints in cochlear development to generate a transcriptomic atlas.